WhaleCreepWhat the best hedge funds own, from their SEC 13F filings
HomeFundsRA Capital Management › Q1 2013

RA Capital Management 13F holdings, Q1 2013

Holdings as of March 31, 2013 · filings on SEC EDGAR · latest filing →

RA Capital Management disclosed 17 US equity positions worth $406.9m in its Q1 2013 13F filing. The largest position was ACAD at 21.1% of the reported book, followed by SGMOQ and KERYX BIOPHARMACEUTICALS INC. Against the Q4 2012 filing, it opened 6 new positions, added to 5 and reduced 1 among the top 17 holdings.

← Q4 2012 · Q2 2013 →

What did RA Capital Management own in Q1 2013? Top 17 positions

#StockSectorWeightValueSharesΔ sharesvs Q4 2012
1 ACAD ACADIA PHARMACEUTICALS INC Healthcare 21.1%$86.0m10,827,545 34% added
2 SGMOQ SANGAMO BIOSCIENCES INC Healthcare 13.6%$55.5m5,808,220 53% added
3 KERYX BIOPHARMACEUTICALS INC 9.8%$39.8m5,647,050 new
4 DYAX CORP 9.1%$37.2m8,528,440 -0% held
5 NVAX NOVAVAX INC Healthcare 8.3%$33.6m14,745,112 2% added
6 HYPERION THERAPEUTICS INC 6.8%$27.6m1,068,380 new
7 SUNESIS PHARMACEUTICALS INC 6.5%$26.6m4,862,230 0% held
8 XOMA CORP DEL 5.7%$23.4m6,698,558 2% added
9 NEWLINK GENETICS CORP 4.8%$19.4m1,579,681 1534% added
10 DERMA SCIENCES INC 4.7%$19.0m1,573,931 0% held
11 SEQUENOM INC 3.6%$14.7m3,540,053 new
12 ARTHROCARE CORP 3.3%$13.5m387,462 0% held
13 STEMLINE THERAPEUTICS INC 1.1%$4.5m394,036 new
14 SENOMYX INC 0.8%$3.2m1,498,750 -62% reduced
15 IMMU IMMUNOMEDICS INC 0.6%$2.4m1,000,000 new
16 TCRT ZIOPHARM ONCOLOGY INC 0.1%$404.0k220,700 new
17 SAVIENT PHARMACEUTICALS INC 0.1%$270.0k1,000,000 0% held

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.